Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 8Lymphoid 7Dermatologic 2Breast 2Other hematologic neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Thyroid Diseases 1Laryngeal Diseases 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 166Cisplatin 112Cetuximab 76Nivolumab 52Carboplatin 51Fluorouracil 48Paclitaxel 42Docetaxel 37Gemcitabine 30Radiotherapy 28Capecitabine 19Cyclophosphamide 18durvalumab 17Injections 17lenvatinib 16atezolizumab 16cemiplimab 15spartalizumab 13fludarabine 13avelumab 12Ipilimumab 12Pemetrexed 11130-nm albumin-bound paclitaxel 11Oxaliplatin 10Gefitinib 10tremelimumab 9Drug Therapy 9tislelizumab 8epacadostat 8budigalimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Vitamin B 12 × Head & Neck × Clear all
NCT01057589 2013-09-18

A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Eli Lilly and Company

Phase 2 Completed
66 enrolled 11 charts
Head & Neck

Head and Neck Neoplasms, Laryngeal Diseases, Thyroid Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡